|
57
|
258
|
4ufgH |
Thrombin in complex with (2r)-2-(benzylsulfonylamino)-n-((1s)-2-((4- carbamimidoylphenyl)methylamino)-1-methyl-2-oxo-ethyl)-n-methyl-3- phenyl-propanamide ethane |
|
3
|
32
|
4rkjA |
Crystal structure of thrombin mutant s195t (free form) |
|
58
|
258
|
4ufeH |
Thrombin in complex with (2r)-2-(benzylsulfonylamino)-n-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-butyl)-3-phenyl-propanamide |
|
1
|
28
|
4uehL |
Thrombin in complex with benzamidine |
|
3
|
36
|
4thnL |
The crystal structure of alpha-thrombin-hirunorm iv complex reveals a novel specificity site recognition mode. |
|
58
|
258
|
4ufdH |
Thrombin in complex with 4-(((1-((2s)-1-((2r)-2-(benzylsulfonylamino)- 3-phenyl-propanoyl)pyrrolidin-2-yl)-1-oxo-ethyl)amino)methyl) benzamidine |
|
1
|
28
|
4udwL |
Thrombin in complex with 1-(2r)-2-amino-3-phenyl-propanoyl-n-(2, 5dichlorophenyl)methylpyrrolidine-2-carboxamide |
|
3
|
28
|
4ufgL |
Thrombin in complex with (2r)-2-(benzylsulfonylamino)-n-((1s)-2-((4- carbamimidoylphenyl)methylamino)-1-methyl-2-oxo-ethyl)-n-methyl-3- phenyl-propanamide ethane |
|
51
|
259
|
4thnH |
The crystal structure of alpha-thrombin-hirunorm iv complex reveals a novel specificity site recognition mode. |
|
3
|
27
|
4ufdL |
Thrombin in complex with 4-(((1-((2s)-1-((2r)-2-(benzylsulfonylamino)- 3-phenyl-propanoyl)pyrrolidin-2-yl)-1-oxo-ethyl)amino)methyl) benzamidine |
|
3
|
28
|
4ufeL |
Thrombin in complex with (2r)-2-(benzylsulfonylamino)-n-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-butyl)-3-phenyl-propanamide |
|
56
|
258
|
4ue7H |
Thrombin in complex with 1-amidinopiperidine |
|
58
|
257
|
4uffH |
Thrombin in complex with (2r)-2-(benzylsulfonylamino)-n-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-ethyl)-n-methyl-3-phenyl- propanamide |
|
1
|
28
|
4ue7L |
Thrombin in complex with 1-amidinopiperidine |
|
56
|
258
|
4ud9H |
Thrombin in complex with 5-chlorothiophene-2-carboxamide |
|
3
|
27
|
4uffL |
Thrombin in complex with (2r)-2-(benzylsulfonylamino)-n-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-ethyl)-n-methyl-3-phenyl- propanamide |
|
57
|
258
|
4uehH |
Thrombin in complex with benzamidine |
|
57
|
258
|
4udwH |
Thrombin in complex with 1-(2r)-2-amino-3-phenyl-propanoyl-n-(2, 5dichlorophenyl)methylpyrrolidine-2-carboxamide |
|
3
|
40
|
4rkoA |
Crystal structure of thrombin mutant s195t bound with ppack |
|
56
|
259
|
4rkjB |
Crystal structure of thrombin mutant s195t (free form) |
|
58
|
257
|
4rkoB |
Crystal structure of thrombin mutant s195t bound with ppack |
|
55
|
290
|
4rn6A |
Structure of prethrombin-2 mutant s195a bound to the active site inhibitor argatroban |
|
125
|
524
|
4nzqA |
Crystal structure of ca2+-free prothrombin deletion mutant residues 146-167 |
|
118
|
557
|
4o03A |
Crystal structure of ca2+ bound prothrombin deletion mutant residues 146-167 |
|
3
|
32
|
4mlfA |
Crystal structure for the complex of thrombin mutant d102n and hirudin |
|
58
|
257
|
4loyH |
Crystal structure analysis of thrombin in complex with compound d57, 5-chlorothiophene-2-carboxylic acid [(s)-2-[2-methyl-3-(2- oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1- yl)-3-oxopropyl]amide (sar107375) |
|
1
|
27
|
4lxbL |
Crystal structure analysis of thrombin in complex with compound d58 |
|
59
|
259
|
4mlfB |
Crystal structure for the complex of thrombin mutant d102n and hirudin |
|
59
|
257
|
4lxbH |
Crystal structure analysis of thrombin in complex with compound d58 |
|
3
|
27
|
4loyL |
Crystal structure analysis of thrombin in complex with compound d57, 5-chlorothiophene-2-carboxylic acid [(s)-2-[2-methyl-3-(2- oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1- yl)-3-oxopropyl]amide (sar107375) |
|
79
|
411
|
4hzhA |
Structure of recombinant gla-domainless prothrombin mutant s525a |
|
53
|
257
|
4htcH |
The refined structure of the hirudin-thrombin complex |
|
3
|
33
|
4htcL |
The refined structure of the hirudin-thrombin complex |
|
2
|
29
|
4hfpA |
Structure of thrombin mutant s195a bound to the active site inhibitor argatroban |
|
3
|
31
|
4h6sA |
Crystal structure of thrombin mutant e14ea/d14la/e18a/s195a |
|
51
|
259
|
4h6sB |
Crystal structure of thrombin mutant e14ea/d14la/e18a/s195a |
|
50
|
257
|
4hfpB |
Structure of thrombin mutant s195a bound to the active site inhibitor argatroban |
|
57
|
306
|
4h6tA |
Crystal structure of prethrombin-2 mutant e14ea/d14la/e18a/s195a |
|
3
|
29
|
3r3gA |
Structure of human thrombin with residues 145-150 of murine thrombin. |
|
51
|
259
|
3r3gB |
Structure of human thrombin with residues 145-150 of murine thrombin. |
|
2
|
29
|
3qdzA |
Crystal structure of the human thrombin mutant d102n in complex with the extracellular fragment of human par4. |
|
54
|
259
|
3qgnB |
The allosteric e*-e equilibrium is a key property of the trypsin fold |
|
3
|
28
|
3qtvL |
Thrombin inhibition by pyridin derivatives |
|
58
|
258
|
3qx5H |
Thrombin inhibition by pyridin derivatives |
|
51
|
257
|
3qdzB |
Crystal structure of the human thrombin mutant d102n in complex with the extracellular fragment of human par4. |
|
57
|
258
|
3qwcH |
Thrombin inhibition by pyridin derivatives |
|
3
|
28
|
3qx5L |
Thrombin inhibition by pyridin derivatives |
|
3
|
28
|
3qtoL |
Thrombin inhibition by pyridin derivatives |
|
57
|
258
|
3qtvH |
Thrombin inhibition by pyridin derivatives |
|
3
|
28
|
3qwcL |
Thrombin inhibition by pyridin derivatives |
